Full Text View
Tabular View
No Study Results Posted
Related Studies
Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
This study is ongoing, but not recruiting participants.
Study NCT00229515   Information provided by Universitaria di Ferrara
First Received: September 27, 2005   Last Updated: January 9, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myocardial Infarction
Additional conditions recognized in this trial
Infarction
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Ischemia
Myocardial Ischemia
Necrosis
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
tirofiban and bare metal stent
Additional drug interventions recognized in this trial
Abciximab
PS-K
Sirolimus
Tirofiban
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Anticoagulants
Antifungal Agents
Antineoplastic Agents
Antiviral Agents
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Immunologic Factors
Immunosuppressive Agents
Interferon Inducers
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Radiation-Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Universitaria di Ferrara


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services